| 产品详情 |
| Edit |   |
|---|
| Product Name | TAFI, Human (Thrombin Activatable Fibrinolysis Inhibitor) |
|---|
| Description | TAFI is prepared from fresh frozen human plasma by a modification of the method of Bajzar, et al. (10). Thrombin Activatable Fibrinolysis Inhibitor (TAFI, Plasma pro-carboxypeptidase B, carboxypeptidase U) is a single chain glycoprotein zymogen (Mr=60,000) synthesized in the liver and circulating at a plasma concentration of 50nM (1-4). Thrombin (plasmin, trypsin) cleavage of the zymogen releases a 92 amino acid N-terminal activation peptide containing 4 N-linked glycosylation sites (N22, N51, N63, N86) and the proposed plasminogen recognition site. The rate of thrombin catalyzed activation of TAFI is increased 1250 fold by formation of a ternary complex with thrombomodulin (5). The 309 amino acid C-terminal (Mr=35,783) catalytic domain (TAFIa, pCPB) displays the properties of a basic carboxypeptidase, hydrolyzing lysine and arginine from the C-terminal position of polypeptides. This portion of the molecule is homologous to tissue carboxypeptidase B and contains 7 conserved cystine res |
|---|
| Size | 50ug |
|---|
| Concentration | n/a |
|---|
| Applications | n/a |
|---|
| Other Names | n/a |
|---|
| Gene, Accession, CAS # | n/a |
|---|
| Catalog # | T0600-95D |
|---|
| Price | |
|---|
| Order / More Info | TAFI, Human (Thrombin Activatable Fibrinolysis Inhibitor) from UNITED STATES BIOLOGICAL |
|---|
| Product Specific References | n/a |
|---|
| 产品资料 |
|
|